2015
DOI: 10.1016/j.ijcard.2014.11.054
|View full text |Cite
|
Sign up to set email alerts
|

Ticagrelor-related dyspnea: An underestimated and poorly managed event?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2015
2015
2018
2018

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(6 citation statements)
references
References 6 publications
(6 reference statements)
0
6
0
Order By: Relevance
“…Early-onset dyspnea related to ticagrelor is typically not caused by heart dysfunctions, usually occurs within the 1st days of treatment and it was traditionally attributed to drug's adenosine-mediated actions, as ticagrelor has a chemical structure similar to that of adenosine. 26 However, given that dyspnea is an adverse event also observed for other antiplatelet reversible agents (i.e. elinogrel), with a different chemical structure compared with adenosine molecule, alternative hypotheses were formulated.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Early-onset dyspnea related to ticagrelor is typically not caused by heart dysfunctions, usually occurs within the 1st days of treatment and it was traditionally attributed to drug's adenosine-mediated actions, as ticagrelor has a chemical structure similar to that of adenosine. 26 However, given that dyspnea is an adverse event also observed for other antiplatelet reversible agents (i.e. elinogrel), with a different chemical structure compared with adenosine molecule, alternative hypotheses were formulated.…”
Section: Discussionmentioning
confidence: 99%
“…Anyway, given the benefits provided by the drug in this subset of patients, we believe that prescribers should consider ticagrelor replacement only in patients who cannot tolerate dyspnea. 26…”
Section: Discussionmentioning
confidence: 99%
“…15 Symptom resolution reportedly occurs after ticagrelor discontinuation, and no underlying pathologic cardiac or pulmonary abnormalities have been identified. [16][17][18] A substudy of patients in the PLATO trial underwent Holter monitoring for 6 days following initiation of treatment. Ventricular pauses lasting !3 seconds occurred in 5.8% of patients in the ticagrelor group versus 3.6% in the clopidogrel group (P ¼ .006).…”
Section: Discussionmentioning
confidence: 99%
“…15 Symptom resolution reportedly occurs after ticagrelor discontinuation, and no underlying pathologic cardiac or pulmonary abnormalities have been identified. 16 18…”
Section: Discussionmentioning
confidence: 99%
“…Antiplatelet drugs are those drugs which prevents the blood platelets from sticking together and forming a blood clot. DAPT is important for preventing stent thrombosis and also the recurrence of ACS events [1][2][3].…”
Section: Introductionmentioning
confidence: 99%